Tue, March 28, 2023

Judah Frommer Maintained (ABOS) at Buy with Decreased Target to $13 on, Mar 28th, 2023

  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. ith-decreased-target-to-13-on-mar-28th-2023.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
  • 🞛 This publication is a summary or evaluation of another publication
  • 🞛 This publication contains potentially derogatory content such as foul language or violent themes
Judah Frommer of Credit Suisse, Maintained "Acumen Pharmaceuticals, Inc." (ABOS) at Buy with Decreased Target from $16 to $13 on, Mar 28th, 2023.

Judah, nor any peers, have made any analyst calls on ABOS in the last 4 months.

Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30